{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002571","form_type":"8-K","ticker":null,"cik":"0001642545","company_name":"Shockwave Medical, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.393070+00:00","generated_at":"2026-06-02T22:09:39.590015+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Shockwave Medical Q1 revenue up 36% to $218.8M, net income $55.3M; withdraws 2024 guidance due to JNJ acquisition","bullets":["Revenue $218.8M (+36% YoY); net income $55.3M ($1.44 diluted EPS) vs $39.1M ($1.01) in Q1 2023.","Gross margin 87%; operating expenses $148.2M (+48% YoY) on sales force expansion.","Adjusted EBITDA $68.5M, up 19% from $57.5M in Q1 2023.","Withdraws full-year 2024 guidance due to proposed Johnson & Johnson acquisition.","Cash, cash equivalents and short-term investments $1,029.2M as of March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002571","json":"https://secwatch.observer/filing/0001171843-24-002571.json","markdown":"https://secwatch.observer/filing/0001171843-24-002571.md","text":"https://secwatch.observer/filing/0001171843-24-002571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642545/000117184324002571/0001171843-24-002571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642545/000117184324002571/f8k_050624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:09:39.590015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5af034bd7167897f0d531dc640e4761724d8d07a","claim":"Shockwave Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $218.8 million, net income $55.3 million, EPS $1.48 and $1.44.","evidence_excerpt":"to bring our life-changing therapies to even more patients across the globe.” First Quarter 2024 Financial Results Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642545/000117184324002571/0001171843-24-002571-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$218.8 million"},{"label":"Net income","value":"$55.3 million"},{"label":"EPS","value":"$1.48 and $1.44"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}